Aaron S. Mansfield

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Amivantamab induces immune-mediated cytotoxicity in mesothelioma via EGFR and MET engagement

  Journal of Thoracic Oncology · 2026-06-01

• Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy

  Clinical Cancer Research · 2026-04-30 · 1 citations

• Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee

  Journal of Thoracic Oncology · 2026-04-10

• Abstract 5547: Enhancing antibody-dependent cellular cytotoxicityin mesothelioma through concurrent EGFR and MET targeting withamivantamab

  Cancer Research · 2026-04-03

• Abstract 94: Liquid biopsy profiling of the tumor microenvironment to determine response to immunotherapy regimens across solid tumors.

  Cancer Research · 2026-04-03

• Abstract 1183: Early ctDNA quantification by ctFE outperforms Max VAF for survival stratification across locally advanced and oligometastatic NSCLC treated with radiotherapy.

  Cancer Research · 2026-04-03

• Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion–Positive Non–Small Cell Lung Cancer

  Journal of Clinical Oncology · 2026-03-26

• Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in &lt;i&gt;RET&lt;/i&gt;-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• Table S1 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in &lt;i&gt;RET&lt;/i&gt;-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial

  JTO Clinical and Research Reports · 2026-03-16 · 1 citations

• Table S2 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in &lt;i&gt;RET&lt;/i&gt;-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• Table S3 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in &lt;i&gt;RET&lt;/i&gt;-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• Supplementary Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in &lt;i&gt;RET&lt;/i&gt;-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomas

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-02-03

• Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i> -Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  Clinical Cancer Research · 2026-01-15 · 1 citations

• Immune Checkpoint Inhibitor Monotherapy for Patients With Pulmonary Sarcomatoid Carcinoma—The Optimal Therapeutic Strategy for This Rare Lung Cancer Subtype?

  Journal of Thoracic Oncology · 2025-12-01

• Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support

  Supportive Care in Cancer · 2025-11-26 · 1 citations

• Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

  2025-11-25

• Supplementary Figure from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

  2025-11-25

• Supplementary Figures 1-8 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma

  2025-11-24